Disease · MONDO_0001920
chronic purulent otitis media
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic purulent otitis media. Diseases, record MONDO_0001920. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001920
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs3
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PAZUFLOXACIN | CHEMBL240163 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CO-TRIMOXAZOLE | CHEMBL58061 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TRIMETHOPRIM | CHEMBL22 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase II | 1 | DNA topoisomerase II inhibitor | Phase 1 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| TOP2B | DNA topoisomerase II | 1 | DNA topoisomerase II inhibitor | Phase 1 | https://conductscience.org/library/genes/7155 | Drugs and targets |
Trials1
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by |
|---|---|---|---|---|---|---|---|
| NCT00189098 | Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media | Not applicable | 101 | 2012-07-13 | Chronic Otitis Media | TRIMETHOPRIM | Its record names the disease |
Source ClinicalTrials.gov
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sulfamethoxazole-trimethoprim vs Placebo: serious adverse events | 1 of 50 | 1 of 51 | 101 | NCT00189098 | Trial comparisons |
| Sulfamethoxazole-trimethoprim vs Placebo: Number of Patients Who Underwent Ear Nose and Throat Surgery Between 12 Weeks and 1 Year Follow-up. | 13 of 44 | 11 of 46 | 90 | NCT00189098 | Trial comparisons |
| Sulfamethoxazole-trimethoprim vs Placebo: Number of Patients Who Used Additional Antibiotic Eardrops Between 6 to 12 Week Follow-up | 21 of 38 | 26 of 39 | 77 | NCT00189098 | Trial comparisons |
| Sulfamethoxazole-trimethoprim vs Placebo: Number of Patients Who Used Systemic Antibiotics Other Than the Study Medication Between 6 and 12 Weeks Follow-up. | 4 of 38 | 7 of 39 | 77 | NCT00189098 | Trial comparisons |
| Sulfamethoxazole-trimethoprim vs Placebo: Number of Patients Who Used Systemic Antibiotics Other Than the Study Medication Between 12 Weeks and 1 Year Follow-up. | 23 of 37 | 18 of 38 | 75 | NCT00189098 | Trial comparisons |
| Sulfamethoxazole-trimethoprim vs Placebo: Number of Patients Who Used Additional Antibiotic Eardrops Between 12 Weeks to 1 Year Follow-up | 29 of 37 | 31 of 38 | 75 | NCT00189098 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001920
GET https://conductscience.org/api/diseases/v1/MONDO_0001920/drugs